Characterization of the glucuronidating pathway of pectolinarigenin, the major active constituent of the Chinese medicine Daji, in humans and its influence on biological activities.

The Chinese medicine Daji (the aerial part of Cirsium japonicum DC.) and its charred product (Cirsii Japonici Herba Carbonisata) have been widely used as hemostatic agents or diuretic agents to prepare a variety of Chinese herbal formula. Pectolinarigenin (PEC), one of the most abundant constituents in both Daji and its charred product, has been considered as the key effective substance responsible for the major pharmacological activities of Daji, including hemostasis, hepatoprotective, anti-tumor and anti-osteoporosis effects. However, the major metabolic pathways of PEC in humans and the influence of PEC metabolism on its biological activities are poorly understood. To characterize the main metabolic pathway(s) and key enzymes of PEC in human biological systems, as well as to reveal the influence of PEC metabolism on its biological activities. The metabolic stability assays of PEC were investigated in human liver microsomes (HLM). The O -glucuronide of PEC was biosynthesized and characterized by nuclear magnetic resonance (NMR) spectroscopy. The key enzymes responsible for O- glucuronidation of PEC in humans were assigned by performing UGT reaction phenotyping, chemical inhibition and enzymatic kinetic assays. The agonist effects of PEC and its O -glucuronide on nuclear factor erythroid2-related factor 2 (Nrf2), Peroxisome proliferator activated receptors (PPARα and PPARβ) were tested at the cellular level. PEC could be readily metabolized to form a mono- O -glucuronide in both human liver microsome (HLM) and human intestinal microsome (HIM). The mono- O -glucuronide was bio-synthesized by mouse liver S9 and its structure was fully characterized as PEC-7- O -β-D-glucuronide (PEC- O -7-G). UGT1A1, UGT1A3 and UGT1A9 are key enzymes responsible for PEC-7- O -glucuronidation in HLM, while UGT1A1, UGT1A9 and 1A10 may play key roles in this reaction in HIM. Biological tests revealed that PEC displayed strong agonist effects on Nrf2, PPARα and PPARβ, whereas PEC-7- O -glucuronide showed relatively weak Nrf2 agonist effect and very weak PPAR agonist effects, indicating that PEC-7- O -glucuronidation strongly weaken its agonist effects on Nrf2 and PPAR. Our results demonstrate that 7- O -glucuronidation is the major metabolic pathway of PEC in human tissues, while UGT1A1, 1A3 and 1A9 are key contributing enzymes responsible for PEC-7- O -glucuronidation in human liver. It is also found that PEC 7- O -glucuronidation significantly weakens the Nrf2 and PPAR agonist effects. All these findings are very helpful for the pharmacologists to deep understand the metabolic rates of PEC in humans. [Display omitted] • PEC- O -glucuronidation is a major metabolic pathway of PEC in humans. • The glucuronide was biosynthesized and fully characterized as PEC-7- O -β-D-glucuronide. • UGT1A1, UGT1A3 and UGT1A7-10 catalyzed PEC-7- O -glucuronidation. • PEC-7- O -glucuronidation strongly reduced the Nrf2 and PPAR agonist effects of PEC. [ABSTRACT FROM AUTHOR]